Daily Subcutaneous injections of Relaxin is a therapy for heart failure with preserved ejection fraction

30 August 2024 (15:00 - 15:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Guy Salama

Upmc University Of Pittsburgh Medical Center, Pittsburgh (United States of America)

7 More presentations in this session

Presentation thumbnail

Interleukin-22 inhibits right ventricular remodelling by a unique mechanism in a pulmonary artery constriction model.

Doctor K. Shibao (Kurume, JP)

Abstract Slides

Presentation thumbnail

Milk-derived extracellular vehicles alleviate heart failure with preserved ejection fraction by modulating gut microbiota

Miss S. Zhang (Singapore, SG)

Abstract Slides Video

Presentation thumbnail

CD14 blockade preserves left ventricular structure and systolic function in a murine model of ST-elevation myocardial infarction.

Doctor D. Donner (Melbourne, AU)

Abstract Slides

Presentation thumbnail

The STRIPAK associated kinase MST4 is a novel mediator in heart failure pathogenesis

Mr M. Leye (Heidelberg, DE)

Abstract Slides

Presentation thumbnail

LCZ696 (sacubitril/valsartan) alleviates residual cardiac remodeling of large ventricular aneurysms after surgical ventricular reconstruction by mediating circMap4k2/LIN28A/PDK1 pathway

Ms J. Yan (Guangzhou, CN)

Abstract Slides Video

Access the full session

Session thumbnail

Heart failure: new scientific insights (1)

The Event

Event poster

ESC Congress 2024

30 August 2024 15:00 CET

You may be interested in

Congress Presentation

RELAXIN-LA in worsening HFpEF

Congress Presentation

Effects of sacubitril-valsartan alone or in combination with dapagliflozin on aging-related heart failure with preserved ejection fraction

Congress Presentation

Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources